资讯

Medpage Today on MSN3 个月
Managing Non-Transfusion-Dependent Thalassemia Presents Challenges
An essential factor in distinguishing thalassemia phenotypes is transfusion dependence. While beta-thalassemia major requires ...
来自MSN21 天
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
The sNDA is supported by data from two phase III studies, ENERGIZE and ENERGIZE-T, which evaluated Pyrukynd for alpha or beta-thalassemia ... its primary endpoint of hemoglobin response, as ...